2013
Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation
Toubai T, Sun Y, Luker G, Liu J, Luker K, Tawara I, Evers R, Liu C, Mathewson N, Malter C, Nieves E, Choi S, Murphy K, Reddy P. Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood 2013, 121: 4231-4241. PMID: 23520337, PMCID: PMC3656455, DOI: 10.1182/blood-2012-05-432872.Peer-Reviewed Original ResearchConceptsAntigen-presenting cellsTumor-specific antigensGVT responseAllo-HCTAPC subsetsDendritic cellsExperimental allogeneic bone marrow transplantationHost-derived antigen-presenting cellsAllogeneic bone marrow transplantationAllogeneic hematopoietic cell transplantationAlloantigen-specific responsesHost-derived CD8Donor T cellsHematopoietic cell transplantationBone marrow transplantationRelevant murine modelStimulation of TLR3Host diseaseTumor effectMarrow transplantationCell transplantationTumor responseSerious toxicityT cellsOptimal graft
2012
CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant
Firpi R, Dong H, Clark V, Soldevila‐Pico C, Morelli G, Cabrera R, Norkina O, Shuster J, Nelson D, Liu C. CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver International 2012, 33: 72-78. PMID: 23107586, PMCID: PMC3518691, DOI: 10.1111/liv.12013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsBiopsyFemaleFloridaGenotypeHepatitis CHumansInterferonsInterleukinsKaplan-Meier EstimateLiver CirrhosisLiver TransplantationLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPolymorphism, Single NucleotideProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTissue DonorsTreatment OutcomeConceptsSustained viral responseInterferon-based therapyLiver transplant patientsCC genotypeRecurrent HCVLiver transplantTransplant patientsIL-28B single nucleotide polymorphismInterleukin (IL) 28B single nucleotide polymorphismsAdult liver transplant patientsPost-transplant HCV recurrenceHepatitis C populationIL-28B genotypeIL-28B polymorphismsInterleukin 28B (IL28B) polymorphismsStrongest pretreatment predictorOverall clinical outcomeBetter treatment responseSingle nucleotide polymorphismsHCV recurrenceHCV patientsHCV therapyLiver transplantationHepatitis COverall survival
2011
Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL
Hanash A, Kappel L, Yim N, Nejat R, Goldberg G, Smith O, Rao U, Dykstra L, Na I, Holland A, Dudakov J, Liu C, Murphy G, Leonard W, Heller G, van den Brink M. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood 2011, 118: 446-455. PMID: 21596854, PMCID: PMC3138694, DOI: 10.1182/blood-2010-07-294785.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGene Knockdown TechniquesGraft vs Host DiseaseGraft vs Leukemia EffectHumansImmunity, InnateInterleukin-21 Receptor alpha SubunitInterleukinsLymphocytes, Tumor-InfiltratingMiceMice, Inbred BALB CMice, Inbred C57BLMice, Inbred DBAMice, KnockoutOrgan SpecificitySignal TransductionTissue DonorsT-LymphocytesTransplantation ImmunologyConceptsSeparation of GVHDDonor T cellsKO T cellsIL-21T cellsTissue-specific modulationGastrointestinal GVHDCytokine productionWild-type donor T cellsDonor regulatory T cellsTh cell cytokine productionPeripheral T cell functionMesenteric lymph nodesRegulatory T cellsTh cell functionIL-21 signalingInflammatory cytokine productionBM transplantation modelT cell functionLymphoma responseLymph nodesProinflammatory cytokinesTransplantation outcomesTransplantation modelGVHDLow prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience
Pan J, Oh S, Soldevila‐Pico C, Nelson D, Liu C. Low prevalence of HBV DNA in the liver allograft from anti‐HBc‐positive donors: a single‐center experience. Clinical Transplantation 2011, 25: 164-170. PMID: 20156222, PMCID: PMC3480317, DOI: 10.1111/j.1399-0012.2010.01211.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCase-Control StudiesDNA, ViralFemaleFollow-Up StudiesGraft SurvivalHepatitis BHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHumansImmunoenzyme TechniquesLiver TransplantationMaleMiddle AgedPolymerase Chain ReactionPrevalenceRetrospective StudiesSurvival RateTissue DonorsTransplantation, HomologousTreatment OutcomeVirus ActivationConceptsHepatitis B virusDetectable HBV DNAHBV DNALiver allograftsLow prevalenceDe novo hepatitis B.Serum HBV DNA levelsHepatitis B core antigenHepatitis B surface antigenHBV DNA levelsSingle-center experienceB core antigenLiver biopsy tissueB surface antigenViral protein expressionHBV serologySeronegative recipientsHBV infectionHepatitis B.Such prophylaxisPositive donorsCore antigenRetrospective studyB virusProphylaxis
2003
Role of CXCR3-induced donor T-cell migration in acute GVHD
Duffner U, Lu B, Hildebrandt G, Teshima T, Williams D, Reddy P, Ordemann R, Clouthier S, Lowler K, Liu C, Gerard C, Cooke K, Ferrara J. Role of CXCR3-induced donor T-cell migration in acute GVHD. Experimental Hematology 2003, 31: 897-902. PMID: 14550805, DOI: 10.1016/s0301-472x(03)00198-x.Peer-Reviewed Original ResearchConceptsRole of CXCR3T cellsAcute GVHDDonor T cell expansionDonor T cell migrationDonor T cellsExpression of CXCR3GVHD target organsDonor cellsEffector T cellsBone marrow transplantation modelDonor T-cell functionMinor histocompatibility antigensT cell expansionWild-type B6Chemokine receptor CXCR3T cell functionWild-type T cellsWild-type donor cellsT cell migrationMigration of donorWild-type donorsAcute graftHost diseaseBMT recipients
2002
Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects
Reddy P, Teshima T, Hildebrandt G, Williams D, Liu C, Cooke K, Ferrara J. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood 2002, 101: 2877-2885. PMID: 12433681, DOI: 10.1182/blood-2002-08-2566.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnimalsBone Marrow TransplantationFemaleGraft vs Host DiseaseGraft vs Leukemia EffectHumansInterferon-gammaInterleukin-18Leukemia, ExperimentalMiceMice, Inbred BALB CMice, Inbred C57BLSTAT6 Transcription FactorSurvival RateT-LymphocytesTissue DonorsTrans-ActivatorsTransplantation, HomologousConceptsAllogeneic bone marrow transplantationBone marrow transplantationPretreatment of donorsIL-18Acute GVHDAcute graftHost diseaseLeukemia effectTransplant donorsCytotoxic T lymphocyte activityAcute GVHD mortalityIL-18 pretreatmentDonor T cellsT lymphocyte activityBM transplant recipientsIL-4 secretionSTAT6-dependent mechanismIL-18 treatmentGVHD mortalityGVL effectPreserves graftTransplant recipientsInterleukin-18Marrow transplantationBM donors